Founder of Biotest Dr. Dr. med h.c. Hans Schleussner passed away

preview

Press Release from 26.11.2015 Biotest founder Dr Hans Schleussner dies
PDF, 25 KB
[ Download ]

Our product range

Our development pipeline

Phase 1

Phase 2

Phase 3

Approval

Launch

Civacir® (Civacir) - Prophylaxis hepatitis C reinfection
Tregalizumab (BT-061) - other diseases
IgM Concentrate (BT-086) - Severe community acquired pneumonia
Indatuximab Ravtansine (BT-062) - Multiple myeloma
Indatuximab Ravtansine (BT-062) - Solid tumors
(BT-063) - Systemic lupus erythematosus
Fibrinogen (BT-524) - Congenital and acquired fibrinogen deficiency
Cytotect 70 (BT-084) - Congenital CMV infection prophylaxis

Pipeline

Overview of all projects and their status from the therapy areas Haematology, Immunology and Intensive care medicine

Further information

Press releases

Biotest enters into an exclusive cooperation agreement ...

19.01.2016, News

Biotest enters into an exclusive cooperation agreement with Kedrion Biopharma for the distribution of Bivigam(R) in the U.S. - Kedrion Biopharma takes over the distribution of Bivigam(R) in the ... [More]

Kreissparkasse Biberach continues to be major sharehold...

14.01.2016, News

Kreissparkasse Biberach continues to be major shareholder of Biotest Dreieich, 14. January 2016. "Biotest has today published a notification of existing voting rights, pursuant to section 41, ... [More]

Pentaglobin(R) showed encouraging results in the treatm...

14.01.2016, News

Pentaglobin(R) showed encouraging results in the treatment of donor specific antibodies after lung transplantation - In lung transplantation early new donor specific antibodies (DSA) are ... [More]

Release according to Article 26, Section 1 of the WpHG ...

14.01.2016, PVR

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for ... [More]

Biotest receives approval in the European Union for the...

12.01.2016, News

Biotest receives approval in the European Union for the early use of Zutectra(R) after liver transplantation - Application of the subcutaneous hepatitis B hyperimmunoglobulin Zutectra(R) ... [More]

Successful start of the operation of the new plasma rec...

10.12.2015, News

Successful start of the operation of the new plasma receiving area and the virological laboratories - Authorities issue operating license for the building - Storage capacity for human plasma ... [More]

Biotest proceeds into phase III programme in congenital...

01.12.2015, News

Biotest proceeds into phase III programme in congenital fibrinogen deficiency - Fibrinogen concentrate shows good efficacy and safety profile based on preliminary data - Preliminary data ... [More]

DGAP-CMS: Biotest AG: Release of the Home Member State ...

30.11.2015, CMS

Biotest AG announces according to Art. 2c WpHG that Germany is the Home Member State. 30.11.2015 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and ... [More]

Biotest receives positive opinion from the European Com...

23.11.2015, News

Biotest receives positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) for the early use of Zutectra(R) after liver transplantation - Market position as a ... [More]

Biotest establishes basis for significantly higher earn...

10.11.2015, News

Biotest establishes basis for significantly higher earnings potential - Profitable core business despite setback in Q3 2015 - Focus on core business increases planning reliability - Good ... [More]

Biotest to present data from TREAT 2b trial at The Ame...

09.11.2015, News

Biotest to present data from TREAT 2b trial at The American College of Rheumatology (ACR) 2015 Annual Meeting - Presentation of clinical results from TREAT 2b trial (T cell REgulating ... [More]

Letter to Shareholders

06.11.2015, News

LETTER TO SHAREHOLDERS November 4, 2015 Dear Shareholders, The past weeks have been challenging for all of us. As you know, we announced impairments totalling EUR 84 million on 20 October 2015, ... [More]

Impairment of US business and change of guidance

20.10.2015, Adhoc

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest: Impairment of US business and change of guidance Dreieich, 20 October 2015: Biotest AG announces to make impairments ... [More]

Impairment of US business and investments in Europe

20.10.2015, News

Biotest: Impairment of US business and investments in Europe Dreieich, 20 October 2015. Biotest AG announces impairments today totalling to EUR 84 million, leading to a negative third-quarter ... [More]

Release according to Article 26, Section 1 of the WpHG ...

13.10.2015, PVR

On October 13, 2015, ETHENEA Independant Investors S.A., Munsbach, Luxembourg has informed us according to Article 21, Section 1 of the WpHG that via shares its Voting Rights on Biotest AG, ... [More]

Biotest reaches the next milestone in the clinical deve...

06.10.2015, News

Biotest reaches the next milestone in the clinical development of its monoclonal antibody BT-063 by starting the clinical phase IIa trial in the indication systemic lupus erythematosus ... [More]

Biotest AG continues cooperation with ADMA Biologics, ...

30.09.2015, News

Biotest AG continues cooperation with ADMA Biologics, Inc. for the RSV hyperimmunoglobulin RI-002 - Biologic Licence Application submitted to Food and Drug Administration after successful ... [More]

Correction of a release from 14.08.2015, 11:11 CET - Bi...

14.08.2015, PVR

On August 13, 2015, BayernInvest Kapitalverwaltungsgesellschaft mbH, 80333 Munich, Germany has informed us according to Article 21, Section 1 of the WpHG that via shares its Voting Rights on ... [More]

Release according to Article 26, Section 1 of the WpHG ...

14.08.2015, PVR

On August 13, 2015, Bayerininvest Kapitalverwaltungsgesellschaft mbH, 80333 Munich, Germany has informed us according to Article 21, Section 1 of the WpHG that via shares its Voting Rights on ... [More]

Biotest increases revenues in first half year 2015 by 8...

11.08.2015, News

Biotest increases revenues in first half year 2015 by 8.9% - Clinical development of BT-061 will be discontinued - Capacity expansion at headquarter Dreieich on schedule - Board of ... [More]

Careers

Careers

Passionate to help us save lives?

Investor Relations

Investor Relations

The primary objective of our Investor Relations activities is an open and up-to-date dialogue with the financial community.

Letter to shareholders

preview

Letter to shareholders - 4.11.2015
PDF, 162 KB
[ Download ]